RYALTRIS

This brand name is authorized in Ecuador, Ireland, Israel, Poland, Romania, UK.

Active ingredients

The drug RYALTRIS contains a combination of these active pharmaceutical ingredients (APIs):

1	Mometasone UNII 04201GDN4R - MOMETASONE FUROATE
	Mometasone is a topical glucocorticoid with local anti-inflammatory properties. It is likely that much of the mechanism for the effects of mometasone lies in its ability to inhibit the release of mediators of the inflammatory cascade.
	Read more about Mometasone
2	Olopatadine UNII 2XG66W44KF - OLOPATADINE HYDROCHLORIDE
	Olopatadine is a potent selective antiallergic/antihistaminic agent that exerts its effects through multiple distinct mechanisms of action.
	Read more about Olopatadine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RYALTRIS Nasal spray, suspension	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R01AD59		R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD59

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	6166-MEE-0421
GB	Medicines & Healthcare Products Regulatory Agency	399706
IL	מִשְׂרַד הַבְּרִיאוּת	9245
PL	Rejestru Produktów Leczniczych	100431398
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67951001, W67951002, W67951003